Skip to main
HROW

HROW Stock Forecast & Price Target

HROW Analyst Ratings

Based on 7 analyst ratings
Strong Buy
Strong Buy 86%
Buy 14%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Harrow is expected to experience significant growth in the coming years due to its strong portfolio of branded ophthalmic pharmaceuticals and continuous investment in R&D to address unmet needs in the eye care market. The recent launch of BYOOVIZ and the successful acquisition of a biosimilar product referencing LUCENTIS reflect the company's strategic focus on innovation and expansion. Despite potential risks, Harrow's strong reputation and partnerships in the industry position them well for continued growth.

Bears say

Harrow is poised for growth with the launch of new products such as Byqlovi and Byooviz in 3Q26 and expected revenue of $350M-$365M in 2026. However, concerns about potential safety issues with IHEEZO may dampen investor confidence. Additionally, an increasing reliance on acquisitions to drive growth raises questions about the sustainability of the company's growth strategy.

HROW has been analyzed by 7 analysts, with a consensus rating of Strong Buy. 86% of analysts recommend a Strong Buy, 14% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Harrow Health Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Harrow Health Inc (HROW) Forecast

Analysts have given HROW a Strong Buy based on their latest research and market trends.

According to 7 analysts, HROW has a Strong Buy consensus rating as of Aug 26, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $69.43, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $69.43, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Harrow Health Inc (HROW)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.